Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 390       
REVIEW ARTICLE
Year : 2011  |  Volume : 134  |  Issue : 3  |  Page : 261-269

Umbilical cord blood: Current status & promise for the future


1 Molecular & Cellular Therapeutics, University of Minnesota, Minneapolis, MN, USA
2 Foundation for Research in Genetics & Endocrinology, Ahmedabad, India

Correspondence Address:
Jayesh Sheth
Foundation for Research in Genetics & Endocrinology, "FRIGE House", Jodhpur Gam Road, Satellite, Ahmedabad 380 015
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21985808

Rights and PermissionsRights and Permissions

Umbilical cord blood (UCB) has been shown to be a suitable source of haematopoietic stem cells (HSCs) for haematopoietic reconstitution. An increase in the number of UCB transplants indicates an expansion of utility in a broad spectrum of disease conditions. Along with the advantages, UCB also has limitations, and hence several investigators are working to further optimize UCB for this use. Beyond haematopoietic transplantation, additional potential applications of UCB include immunotherapy, tissue engineering and regenerative medicine. UCB banking has improved with time largely due to involvement of professional organizations and their published standards. However, accreditation of these organizations remains voluntary, and in India three of ten banks are public with the remaining being private. Only one public and one private bank are American Association of Blood Banks (AABB) accredited in India. Government agencies need to provide regulatory and safety oversight, which is lacking in serveral countries. Public policy regarding UCB is in its infancy throughout most of the world. Ethical issues, including access to UCB banking and use as therapy for diseases other than haematological and metabolic disorders are in the early phase of trials and remain speculative.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3833    
    Printed91    
    Emailed3    
    PDF Downloaded973    
    Comments [Add]    

Recommend this journal